Bildnachweis: BIO Deutschland, BioM, EY, BCG, Biomed X, VC Magazin, Pixabay. In principle, Germany has excellent prerequisites, but does not currently play a leading role internationally in the life ...

Bildnachweis: PwC. For corporations seeking to maintain a competitive edge and corporate venture capital (CVC) arms striving ...

There are many uncertainties in the world, but this much is certain: the demand for innovative life sciences solutions will continue to grow, from research to therapy development. Despite regulatory ...

Bildnachweis: Life Science Factory, Avocet Bio, VC Magazin, Pixabay. The Life Science Factory offers founders from research ...

Bildnachweis: ITM Isotope Technologies Munich SE, VC Magazin, Pixabay. As the global demand for targeted cancer therapies ...

For everyone who likes obscure abbreviations, sustainability regulations these days are a gold mine. NFRD, SFDR, CSRD, ESRS, TCFD — name a four-letter abbreviation and there’s a fair chance some ...

The IPO of young, innovative growth companies in Germany has hardly been successful to date, as the associated cost, publicity and transparency requirements still place a heavy burden on them. With ...

When using AI in clinical trials, stakeholders point to the challenges associated with the use of AI in clinical trials, amongst others the need to ensure transparency by tracking the AI logic which ...

The current environment is one of increased regulation and scrutiny, which has led to increased pressure on firms’ CFOs and COOs to manage their risks more effectively. This posed many interesting ...

Gitex Global is the world’s largest tech and start-up event and gathers more than 5,000 companies and more than 100,000 visitors from 170 countries.. As a hub between Europe, Asia and Africa, the ...

Bildnachweis: VC Magazin, Pixabay. Zusammen mit Dr. Manfred Wolter (Ministerialdirigent im Bayerischen Wirtschaftsministerium ...

Bildnachweis: Andreas Gebert, VC Magazin. Das bayerische Start-up-Netzwerk BayStartUP erweitert die Geschäftsführung. Zum 1.